bluebird bio

bluebird bio is a biotechnology company focused on developing curative gene therapies for severe genetic diseases. With a decade of experience, the company has pioneered gene therapy treatments for conditions such as beta-thalassemia, cerebral adrenoleukodystrophy, and sickle cell disease. Their FDA-approved one-time gene therapy for sickle cell disease highlights their commitment to delivering life-changing treatments. bluebird bio leverages proprietary lentiviral vector gene therapies, offering a functional copy of a gene to a patient's own cells. The company emphasizes diversity, equity, inclusion, and patient advocacy as part of its mission to improve patient outcomes and drive the field of gene therapy forward.